Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.

But Regeneron believes that, ... “We’re still in the early innings,” said Dr. Israel Lowy, Regeneron’s vice president of clinical development. “As they say in Sherlock Holmes, ...

Regeneron is back with long ... and that we are en route to potentially having much better data than what's out there already with the BMS Opdualag,” Israel Lowy, M.D., Ph.D., Regeneron’s SVP ...

Regeneron also touted an 80% reduction in ... physicians and has the potential to be practice changing,” Regeneron’s clinical development unit head of oncology Israel Lowy told ...

Israel Lowy. So work at Regeneron for a long time has been exploring the potential of biospecifics. And without being too glib, any high school students can make a biospecific in the lab, ...

We have made a commitment to developing an ADC platform in house,” said Israel Lowy, M.D., Ph.D., senior vice president of clinical sciences and head of translational science and oncology at ...

Dr Israel Lowy, senior vice president of translational and clinical sciences in Oncology at Regeneron, said: “Despite recent advancements in the prevention and treatment of cervical cancer ...

We’ve seen some amazing improvements in patients,” Israel Lowy, M.D., Ph.D., Regeneron's senior vice president of translational and clinical science in oncology, said in an interview at the time.